Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Trial Profile

A Phase 1/2 Study Evaluating the Safety and Efficacy of IOV-2001 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin-2 (Primary) ; Peripheral blood lymphocytes-Iovance Biotherapeutics/Ohio State University Comprehensive Cancer Center (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Iovance Biotherapeutics
  • Most Recent Events

    • 04 Nov 2019 Status changed from planning to recruiting, according to an Iovance Biotherapeutics media release.
    • 04 Nov 2019 According to an Iovance Biotherapeutics media release, patient dosing in this study is planned before the end of 2019.
    • 04 Nov 2019 According to an Iovance Biotherapeutics media release, the IND application has been accepted by the FDA and this study has been cleared to proceed. This study is currently active at one clinical site.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top